TriSalus Life Sciences Announces Launch of PREDICTT Clinical Trial Evaluating Pressure-Enabled Drug Delivery in Liver Tumors
TriSalus Life Sciences announced the initiation of the PREDICTT clinical trial to evaluate its Pressure-Enabled Drug Delivery (PEDD) approach in patients with primary or metastatic liver tumors. The investigator-led study at The University of Texas MD Anderson Cancer Center will enroll approximately 20 patients to assess how the TriNav Infusion System impacts tumor targeting and radiation dose distribution when used with Y90 radioembolization.
Key figures
- Nct id
- NCT07444645
- Enrollment target
- 20
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.